Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2025
Comparison of five-year physical outcomes in patients undergoing laparoscopic sleeve gastrectomy plus jejunojejunal bypass versus Roux-en-Y gastric bypass.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guan Wei, Lin Shibo, Shen Jiajia, Liu Ruiping, Yang Ningli, Liang Hui
Аннотация
BACKGROUND: Sleeve gastrectomy plus jejunojejunal bypass (SG + JJB) is increasingly accepted as a surgical treatment for severe obesity. However, data on the long-term results of this procedure are limited, and studies comparing it with other bariatric procedures are scarce.
OBJECTIVES: The objective of this study was to compare 5-year outcomes following SG + JJB and Roux-en-Y gastric bypass (RYGB).
SETTING: The study was conducted at University Hospital, P.R. China.
METHODS: We compared all SG + JJB and RYGB cases handled at our institution between June 2015 and December 2018. We included 329 patients: 167 underwent SG + JJB, and 162 underwent RYGB. All patients completed assessments at presurgery and 5 years after surgery. The data were analyzed using the χ2 test and independent sample t test, with P < .05 denoting statistical significance.
RESULTS: There was no statistically significant difference between the SG + JJB and RYGB groups in terms of weight loss or remission of most associated metabolic complications, such as hypertension, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), hyperuricemia, and obstructive sleep apnea syndrome (OSAS), although the remission rate of hyperlipidemia was higher in the RYGB group (P < .01). Compared with RYGB, SG + JJB results in lower incidences of dumping syndrome, cholelithiasis, anemia, and gastrointestinal dysfunction (P < .01), and a higher rate of gastroesophageal reflux disease (GERD) (P < .01).
CONCLUSIONS: SG + JJB results in sustained weight loss and co-morbidity control after 5 years, yielding a low incidence of adverse events. Like RYGB, SG + JJB seems to be a safe and effective surgical procedure for treating obesity and related diseases.
OBJECTIVES: The objective of this study was to compare 5-year outcomes following SG + JJB and Roux-en-Y gastric bypass (RYGB).
SETTING: The study was conducted at University Hospital, P.R. China.
METHODS: We compared all SG + JJB and RYGB cases handled at our institution between June 2015 and December 2018. We included 329 patients: 167 underwent SG + JJB, and 162 underwent RYGB. All patients completed assessments at presurgery and 5 years after surgery. The data were analyzed using the χ2 test and independent sample t test, with P < .05 denoting statistical significance.
RESULTS: There was no statistically significant difference between the SG + JJB and RYGB groups in terms of weight loss or remission of most associated metabolic complications, such as hypertension, type 2 diabetes mellitus (T2DM), nonalcoholic fatty liver disease (NAFLD), hyperuricemia, and obstructive sleep apnea syndrome (OSAS), although the remission rate of hyperlipidemia was higher in the RYGB group (P < .01). Compared with RYGB, SG + JJB results in lower incidences of dumping syndrome, cholelithiasis, anemia, and gastrointestinal dysfunction (P < .01), and a higher rate of gastroesophageal reflux disease (GERD) (P < .01).
CONCLUSIONS: SG + JJB results in sustained weight loss and co-morbidity control after 5 years, yielding a low incidence of adverse events. Like RYGB, SG + JJB seems to be a safe and effective surgical procedure for treating obesity and related diseases.